Prevalence of Comorbidities in Asthma and Nonasthma Patients

A Meta-analysis

Xinming Su, MD, Yuan Ren, MM, Menglu Li, MM, Xuan Zhao, MM, Lingfei Kong, MD, and Jian Kang, MD

Abstract: This study compares the prevalence rates of comorbidities between asthma and nonasthma control patients reported in the literature.

Literature was searched in several electronic databases. After the selection of studies by following precise eligibility criteria, meta-analyses of odds ratios were carried out with subgroup and sensitivity analyses.

Eleven studies studying 117,548 asthma patients compared with 443,948 non-asthma controls were included in the meta-analysis. The prevalence of cardiovascular comorbidities (odds ratio [OR]: [95% CI] 1.90 [1.70, 2.14]; P < 0.00001), cerebrovascular comorbidities (OR 1.44 [1.29, 1.60]; P < 0.00001), obesity (OR 1.51 [1.14, 2.01]; P < 0.00001), hypertension (OR 1.66 [1.47, 1.88]; P < 0.00001), diabetes (OR 1.25 [1.08, 1.44]; P < 0.00001), other metabolic and endocrine comorbidities (OR 1.60 [1.40, 1.83]; P < 0.00001), psychiatric and neurological comorbidities (OR 1.62 [1.44, 1.82]; P < 0.00001), gut and urinary comorbidities (OR 1.91 [1.47, 2.49]; P < 0.00001), cancer (OR 1.17 [1.10, 1.25]; P < 0.00001), and respiratory comorbidities (OR 5.60 [4.22, 7.44]; P < 0.00001) were significantly higher in the asthma patients in comparison with nonasthma controls.

Asthma is associated with significantly higher comorbidities including cardiovascular, cerebrovascular diseases, obesity, hypertension, diabetes, psychiatric and neurological comorbidities, gut and urinary conditions, cancer, and respiratory problems other than asthma. Respiratory comorbidities are found 5 times more prevalent in asthma than in non-asthma patients.

INTRODUCTION

Asthma is a common inflammatory disorder of the respiratory tract, which is characterized by the obstruction and hyper-responsiveness of the tracheo-bronchial system. Repeated episodic shortness of breath with variable expiratory flow, wheezing, recurrent cough, excessive mucus production by the lining of air passage and chest tightness are the major symptoms of this disease. Asthma is recognized as a heterogeneous disease as multiple subtypes of this disease with distinct pathophysiological mechanisms are identified. 

Estimates of asthma in elderly patients (>60 years of age) indicate 4% to 13% prevalence. Asthma is an important cause of morbidity and disability in individuals over 65 years of age as control of this disease worsens in later age, which is also associated with increased emergency medicine as well as hospitalizations.

Comorbidities are increasingly recognized as important determinants of asthma management and prognosis as these are associated with inadequate disease control, higher healthcare use, and poor quality of life. Moreover, the recurrent exacerbations in asthma are associated with specific co-morbidities that require additional therapeutic interventions. In elderly, especially, the comorbidities are associated with higher mortality, poor adherence to therapeutic interventions, and reduced quality of life.

Although a considerable number of studies have documented the prevalence of comorbidities in asthma patients, comparative controlled studies are relatively less in number. The aim of the present study was to undertake a systematic literature search and to perform a meta-analysis of the studies which compared the prevalence of comorbidities in asthma and nonasthma patients in order to examine the significance of difference in the prevalence of various comorbidities between asthma patients and nonasthma controls.

METHODS

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines are followed while performing this meta-analysis and associated systematic review. As this study is a meta-analysis research with the published data as materials, it does not need the approval from the institutional review board.

Literature Search

Several electronic databases including Embase, Google Scholar, Ovid SP, PubMed/Medline, and Web of Science were searched for the relevant articles. The major medical subject headings (MeSH) and keywords used in different logical combinations and phrases included asthma, comorbidity/comorbidities, prevalence, cardiovascular, heart disease, stroke, myocardial infarction,
thrombosis, atherosclerosis, hypertension, diabetes, obesity, thyroid disease, skin disease, cancer, malignancy, psychiatric disorders, depression, neurological disorders, psychosis, respiratory conditions, gastrointestinal diseases, and musculoskeletal disorders. The search encompassed original research papers published before November 2015.

Inclusion and Exclusion Criteria

The inclusion criterion was: studies reporting the prevalence of the comorbidities in asthma patients by comparing with suitable nonasthma control patients. The exclusion criteria were: (a) studies providing comorbidity prevalence data in asthma patients without control data or studies utilizing asthma/chronic obstructive pulmonary disease controls; studies utilizing indirect data such as medical claims; study reports with data in forms that were unable to be utilized in the meta-analyses of odds ratios.

Data Extraction, Synthesis, and Statistical Analysis

Required data and corresponding demographics were obtained from the selected research articles and synthesized on spreadsheets for use in the meta-analyses. Meta-analyses were carried out with RevMan (Version 5.3; Cochrane Collaboration) software under fixed effects as well as random effects models. For the meta-analyses, the prevalence data were used to calculate the odds ratios of each study data and the overall effect sizes were generated, which was a weighted average of the inverse variance adjusted effect sizes of individual studies (odds ratios [OR] along with 95% CI). Between studies consistency was tested by the $I^2$ index. Subgroup analyses were carried out and sensitivity analyses performed in order to explore the authenticity of results and sources of higher heterogeneity. Publication bias assessment was made by the visual examination of the funnel plot symmetry.

RESULTS

Eleven studies$^{10–20}$ were selected by following the eligibility criteria (Figure 1). Overall, these studies analyzed 117,548 asthma patients and 443,948 nonasthma control patients. Average age (mean ± standard deviation; range) of asthma patients was 57.23 ± 11.65 (18.4 ± 17.8 to 76.4 ± 4.7) years. Gender distribution in the overall population was: 47.1 ± 7.1 % males and 52.3 ± 7.1 % females. A considerable publication bias was evident from the visual examination of the funnel plots (Figure 2).

Cardiovascular and cerebrovascular comorbidities included arrhythmia, atrial fibrillation, congenital heart disease, congestive heart failure, coronary artery disease, ischemic heart disease, heart failure, myocardial infarction, peripheral artery disease, valve disease, and stroke. Metabolic comorbidities included diabetes mellitus, dyslipidemia, hyperlipidemia, hypertension, hyperthyroidism, hypothyroidism, obesity, and
fluid/electrolyte disorders. Neurological and psychiatric comorbidities included autism, anxiety, cerebral palsy, dementia, depression, cognitive impairment, hemiplegia, otitis, and psychosis.

Gastrointestinal and urinary comorbidities included gastroesophageal reflux disease, hernia, liver disease, ulcer, and renal disease/failure. Respiratory comorbidities included chronic bronchitis, respiratory infections, allergy rhinitis, chronic obstructive pulmonary disease, and sinusitis. Other comorbidities included cataract, alcohol/drug abuse, dermatitis, anemia, coagulopathy, and acquired immunodeficiency syndrome (AIDS).

The odds ratios of the prevalence of comorbidities including cardiovascular and cerebrovascular comorbidities (Figure 3), hypertension, diabetes mellitus, obesity, other metabolic, and endocrine comorbidities (Figure 4), neurological and psychiatric comorbidities, gastrointestinal and urinary comorbidities, respiratory comorbidities, cancer, and other some other disease were significantly higher in asthma patients than in nonasthma control patients (Table 1; Figures 5–8). Arthritis was the only disease which was not statistically significantly differently prevalent between asthma and nonasthma patients under the random effects model.

DISCUSSION

The present study has compared asthma patients with nonasthma control patients and has found that asthma is associated with significantly higher comorbidities. Almost all types respiratory, cardiovascular, cerebrovascular, metabolic, gastrointestinal, urinary, neurological, and psychiatric, were significantly higher in asthma patients. Only rheumatoid arthritis was found to be statistically indifferent between asthma and nonasthma patients.

Chronic inflammatory conditions appear to be an important factor for the development of comorbidities, for example, asthma is associated with an increased the risk of cardiovascular disease which is attributed to systemic inflammation. Moreover, in poorly controlled respiratory obstructive conditions, the use of systemic steroids, reduced activity/exercise, and poor sleep can promote comorbidities such as obesity, diabetes, depression, osteoporosis, and pneumonia. A comorbid condition can also develop or promote other comorbidities. While comparing the comorbid patterns of 292 obese and 383 nonobese asthmatic patients, Shah and Yang found that the prevalence of diabetes, lipid disorders, and hypertension was significantly higher in obese asthmatics. Moreover, obese patients are found to have about 2.5 times higher risk of developing asthma, asthma is found more severe in obese individuals, and obesity is associated with poor asthma control. Bariatric surgery of morbidly obese patients with asthma has been found to significantly improve airway function and airway hyper-responsiveness.
besides improving asthma control and systemic inflammation markers.\(^2\)

With aging, the number of comorbid conditions in asthma patients increase. Tsai et al\(^{27}\) in a sample population of 1,195,109 asthma patients found that the overall prevalence of 10 selected comorbidities was <1% in patients with under 18 years of age, 3.4% in 18 to 54 years age group, and 12% in patients over 55 years of age. In young individuals, the percentage of asthmatic patients with one kind of comorbidity was 34% and with >1 kinds of comorbidity was 11%.\(^{28,29}\) Other studies have also reported significantly higher prevalence of comorbidities in elderly in comparison with nonelderly asthma patients.\(^{30,31}\) Recently, Zein et al\(^{32}\) have found that after adjusting comorbidities and asthma duration, severity of asthma was significantly higher in individuals >45 years of age.

It is now agreed that asthma in late age is common and relatively less-recognized, underdiagnosed, and undertreated health problem that affects the quality of health and life. It is also speculated that asthma in elderly is causally and phenotypically different from young-age asthma with impact on the diagnosis, assessment, and management.\(^{33}\) Although Wardzyńska et al\(^{30}\) who reported that in elderly asthmatics comorbidities are more prevalent than in nonelderly patients, but apparently this was not having direct impact on asthma control in patients under specialist care, other authors are concerned about potential impacts of comorbidities and their management such as issues related to drug interactions and adverse events resulting from polypharmacy and adherence to therapy.\(^{34}\) Gershon et al\(^{6}\) who also observed significantly higher comorbidity in asthmatics than in controls, noted that asthma comorbidities

| FIGURE 4. Forest plots showing significantly higher prevalence of metabolic comorbidities in asthma patients. dis. = disease/disorder, DYSLIP = dyslipidemia, HYPLIP = hyperlipidemia, THY = thyroid. |
|---|
| Study or Subgroup | Asthmatics | Controls | Odds Ratio | Study or Subgroup | Odds Ratio |
| Hypertension | Ben-Noun 2001 | 32 | 141 | 106 | 423 | 5.6% | 0.88 [0.56, 1.38] |
| | Cheng 2015 | 5903 | 10455 | 19807 | 41820 | 24.8% | 1.44 [0.21, 1.26] |
| | Pakhare 2010 None-obese | 14 | 181 | 5 | 73 | 3.2% | 1.14 [0.40, 3.29] |
| | Pakhare 2010 Obese | 43 | 165 | 19 | 77 | 3.3% | 1.08 [0.58, 2.01] |
| | Patel 2014 | 146 | 3041 | 482 | 60198 | 15.8% | 2.92 [2.42, 3.52] |
| | Supra 2005 | 3624 | 27493 | 16111 | 27493 | 23.9% | 1.71 [1.60, 2.18] |
| | Shen 2015 | 15898 | 38840 | 46377 | 155347 | 25.4% | 1.83 [1.59, 2.17] |
| | Subtotal (95% CI) | 83625 | 285521 | 100.0% | 1.66 [1.47, 1.88] |
| Total events | 24678 | 157786 | 84507 |
| *Heterogeneity:* Tau² = 0.01; Chi² = 77.24, df = 6 (P < 0.00001); I² = 92%  
*Test for overall effect: Z = 6.28 (P < 0.00001)* |

| Study or Subgroup | Asthmatics | Controls | Odds Ratio | Study or Subgroup | Odds Ratio |
| Diabetes mellitus | Balkrishnan 2000 | 83 | 647 | 638 | 4874 | 13.5% | 0.98 [0.76, 1.25] |
| | Bella 2007 | 23 | 210 | 126 | 1027 | 6.5% | 0.88 [0.55, 1.41] |
| | Ben-Noun 2001 | 23 | 141 | 53 | 423 | 5.5% | 1.36 [0.80, 2.32] |
| | Cheng 2015 | 2751 | 10455 | 9206 | 41820 | 21.9% | 1.27 [1.23, 1.31] |
| | Pakhare 2010 None-obese | 4 | 165 | 2 | 77 | 7.0% | 0.93 [0.75, 0.02] |
| | Pakhare 2010 Obese | 13 | 181 | 9 | 73 | 2.3% | 0.55 [0.22, 1.35] |
| | Patel 2014 | 25 | 6350 | 121 | 60298 | 7.4% | 1.97 [1.28, 3.03] |
| | Supra 2005 | 1801 | 27493 | 1130 | 27493 | 20.8% | 1.64 [1.52, 1.77] |
| | Shen 2015 | 3672 | 38840 | 1282 | 155347 | 21.9% | 1.15 [1.10, 1.19] |
| | Subtotal (95% CI) | 84482 | 291432 | 100.0% | 1.48 [1.18, 1.74] |
| Total events | 8395 | 24265 |
| *Heterogeneity:* Tau² = 0.02; Chi² = 81.08, df = 8 (P < 0.00001); I² = 90%  
*Test for overall effect: Z = 3.05 (P < 0.0002)* |

| Study or Subgroup | Asthmatics | Controls | Odds Ratio | Study or Subgroup | Odds Ratio |
| Obesity | Bella 2007 | 67 | 210 | 236 | 1027 | 19.6% | 1.57 [1.14, 2.17] |
| | Ben-Noun 2001 | 18 | 227 | 59 | 423 | 12.0% | 0.90 [0.51, 1.59] |
| | Cheng 2015 | 2751 | 10455 | 9206 | 41820 | 21.9% | 1.27 [1.23, 1.31] |
| | Pakhare 2010 | 165 | 346 | 77 | 150 | 17.8% | 0.95 [0.69, 1.32] |
| | Supra 2005 | 437 | 27493 | 220 | 27493 | 24.2% | 2.00 [1.70, 2.36] |
| | Shen 2015 | 675 | 38840 | 1269 | 155347 | 25.6% | 2.15 [1.95, 2.36] |
| | Subtotal (95% CI) | 67039 | 184446 | 100.0% | 1.51 [1.14, 2.61] |
| Total events | 1362 | 1861 |
| *Heterogeneity:* Tau² = 0.08; Chi² = 30.25, df = 4 (P < 0.00001); I² = 87%  
*Test for overall effect: Z = 2.85 (P < 0.004)* |

| Study or Subgroup | Asthmatics | Controls | Odds Ratio | Study or Subgroup | Odds Ratio |
| Other metabolic/endocrine | Ben-Noun 2001 HYPLIP | 11 | 141 | 29 | 423 | 3.0% | 1.15 [0.56, 2.37] |
| | Ben-Noun 2001 THY dis. | 9 | 141 | 29 | 423 | 2.7% | 0.83 [0.43, 2.01] |
| | Cheng 2015 DYSLIP | 5936 | 10455 | 11065 | 41820 | 21.9% | 1.27 [1.23, 1.31] |
| | Cheng 2014 HYPLIP | 5063 | 31556 | 15065 | 215157 | 20.1% | 1.40 [1.35, 1.45] |
| | Supra 2005 Fluid/Electrolyte disorder | 1311 | 27493 | 498 | 27493 | 18.2% | 2.71 [2.44, 3.01] |
| | Supra 2005 THY dis. | 415 | 27493 | 239 | 27493 | 15.9% | 1.75 [1.49, 2.05] |
| | Shen 2015 HYPLIP | 8781 | 38840 | 25921 | 155347 | 20.2% | 1.66 [1.42, 1.95] |
| | Subtotal (95% CI) | 139199 | 78158 | 100.0% | 1.60 [1.48, 1.73] |
| Total events | 19056 | 53379 |
| *Test for subgroups differences: Chi² = 9.76, df = 3 (P = 0.02); I² = 69.3%*
**TABLE 1.** Results of the Meta-Analyses

| Comorbidities                  | Studies/Datasets | Asthma Patients | Odds ratios [95% CI]; Significance level |
|-------------------------------|-----------------|-----------------|------------------------------------------|
|                               |                 | Fixed Effects   | Random Effect                            | $I^2$  |
| Cardiovascular                | 16              | 294,727         | 1.75 [1.72, 1.78]; $P < 0.00001$            | 95%   |
| Cerebrovascular               | 6               | 77,199          | 1.43 [1.38, 1.49]; $P < 0.00001$            | 66%   |
| Hypertension                  | 7               | 83,625          | 1.60 [1.57, 1.63]; $P < 0.00001$            | 92%   |
| Diabetes mellitus             | 9               | 84,482          | 1.24 [1.21, 1.28]; $P < 0.00001$            | 90%   |
| Obesity                       | 5               | 67,030          | 1.95 [1.81, 2.11]; $P < 0.00001$            | 87%   |
| Endocrine/metabolic           | 7               | 371,056         | 1.45 [1.42, 1.48]; $P < 0.00001$            | 96%   |
| Psychiatric and neurological  | 17              | 175,784         | 1.83 [1.78, 1.89]; $P < 0.00001$            | 91%   |
| Gastrointestinal and urinary  | 9               | 132,402         | 1.81 [1.71, 1.91]; $P < 0.00001$            | 93%   |
| Respiratory comorbidities     | 9               | 165,224         | 1.5 [5.07, 5.24]; $P < 0.00001$             | 99%   |
| Cancer                        | 4               | 59,637          | 1.17 [1.10, 1.25]; $P < 0.00001$            | 0%    |
| Arthritis                     | 4               | 34,550          | 2.17 [1.89, 2.48]; $P < 0.00001$            | 97%   |
| Other diseases                | 11              | 69,747          | 1.67 [1.55, 1.81]; $P < 0.00001$            | 61%   |

CI = confident interval.

**FIGURE 5.** Forest plots showing significantly higher prevalence of neurological and psychiatric comorbidities in asthma patients. ANX = anxiety, COGN = cognitive impairment, DEM = dementia, DEP = depression, dis. = disease/disorder.

**FIGURE 6.** Forest plots showing significantly higher prevalence of gastrointestinal and urinary comorbidities in asthma patients. dis = disease/disorder, GERD = gastro-esophageal reflex disease.
were associated with poor asthma control, increased health care utility, and decreased quality of life, but the management of comorbidities could significantly improve the outcomes. Thus, comorbidity should be considered with more emphasis in asthma control strategies and should be an important component of covariate analyses in studies with subjective health outcomes.\textsuperscript{35} Among the foremost limitations of the present study, high statistical heterogeneity representing lower consistency between studies in some comparisons is an important consideration. However, because of the epidemiological nature of the present study, the impact of higher statistical heterogeneity may be less on the overall outcomes. Thus, the availability of more

\begin{figure}
\centering
\includegraphics[width=\textwidth]{forest_plot_1}
\caption{Forest plots showing significantly higher prevalence of respiratory comorbidities in asthma patients. Bronch = bronchitis, ch = chronic, COPD = chronic obstructive pulmonary disease, Infect = infection/s, Resp = respiratory.}
\end{figure}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{forest_plot_2}
\caption{Forest plots showing significantly higher prevalence of cancer and other comorbidities in asthma patients. However, the prevalence of arthritis was not significantly different between asthma and nonasthma patients.}
\end{figure}
data in future can refine these findings. Another constraint is that majority of the included studies reported selected comorbidities so not all comorbid conditions could be studied here and some comparisons remained underpowered.

**CONCLUSION**

Asthma is associated with significantly higher comorbid conditions including cardiovascular and cerebrovascular comorbidities, obesity, hypertension, diabetes, metabolic and endocrine conditions, psychiatric and neurological comorbidities, gut and urinary comorbidities, cancer, and respiratory problems other than asthma. Respiratory comorbidities are found 5 times more prevalent in asthma than in nonasthma patients. Management of comorbidities in asthma control strategies can improve outcomes.

**REFERENCES**

1. Boulet LP, Boulay ME. Asthma-related comorbidities. Expert Rev Respir Med. 2011;5:377–393.
2. Stachler RJ. Comorbidities of asthma and the unified airway. Int Forum Allergy Rhinol. 2015;5(Suppl 1):S17–22.
3. Erle DJ, Sheppard D. The cell biology of asthma. J Cell Biol. 2014;205:621–631.
4. McHugh MK, Symanski E, Pompeii LA, et al. Prevalence of asthma among adult females and males in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2001-2004. J Asthma. 2009;46:759–766.
5. Banerji A, Clark S, Afifalo M, et al. Prospective multicenter study of acute asthma in younger versus older adults presenting to the emergency department. J Am Geriatr Soc. 2006;54:48–55.
6. Gershon AS, Guan J, Wang C, et al. Describing and quantifying asthma comorbidity: a population study. PLoS One. 2012;7:e34967doi: 10.1371/journal.pone.0034967.
7. ten Brinke A, Sterk PJ, Mascllee AA, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J. 2005;26:812–818.
8. Pinto Pereira LM, Seemungal TA. Comorbid disease in asthma: the importance of diagnosis. Expert Rev Respir Med. 2010;4:271–274.
9. Moher D, Liberati A, Tetzlaff J, et al. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med. 2009;6:e1000097doi: 10.1371/journal.pmed.1000097.
10. Balkrishnan R, Anderson RT, Bowton D. Self-reported health status predictors of healthcare services utilization and charges in elderly asthmatic patients. J Asthma. 2000;37:415–423.
11. Bellia V, Pedone C, Catalano F, et al. Asthma in the elderly: mortality rate and associated risk factors for mortality. Chest. 2007;132:1175–1182.
12. Ben-Noun L. Characteristics of comorbidity in adult asthma. Public Health Rev. 2001;29:49–61.
13. Cheng CM, Wu YH, Tsai SJ, et al. Risk of developing Parkinson’s disease among patients with asthma: a nationwide longitudinal study. Allergy. 2015;70:1605–1612.
14. Chung WS, Lin CL, Ho FM, et al. Asthma increases pulmonary thromboembolism risk: a nationwide population cohort study. Eur Respir J. 2014;43:801–807.
15. de Miguel Diez J, Hernandez Barrera V, Puente Maestu L, et al. Psychiatric comorbidity in asthma patients. Associated factors. J Asthma. 2011;48:253–258.
16. Dyer CA, Hill SL, Stockley RA, et al. Quality of life in elderly subjects with a diagnostic label of asthma from general practice registers. Eur Respir J. 1999;14:39–45.
17. Pakhalé S, Doucette S, Vandenheen K, et al. A comparison of obese and nonobese people with asthma: exploring an asthma–obesity interaction. Chest. 2010;137:1316–1323.
18. Patel MR, Leo HL, Baptist AP, et al. Asthma outcomes in children and adolescents with multiple morbidities: Findings from the National Health Interview Survey. J Allergy Clin Immunol. 2015;135:1444–1449.
19. Sapra S, Nielsen K, Martin BC. The net cost of asthma to North Carolina Medicaid and the influence of comorbidities that drive asthma costs. J Asthma. 2005;42:469–477.
20. Shen TC, Lin CL, Wei CC, et al. Risk of obstructive sleep apnea in adult patients with asthma: a population-based cohort study in Taiwan. PLoS One. 2015;10:e0128461doi: 10.1371/journal.pone.0128461.
21. Barnig C, Levy BD. Inmate immunity is a key factor for the resolution of inflammation in asthma. Eur Respir Rev. 2015;24:141–153.
22. Shah R, Yang Y. Health and economic burden of obesity in elderly individuals with asthma in the United States. Popul Health Manag. 2015;18:186–191.
23. Camargo CA Jr, Weiss ST, Zhang S, et al. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med. 1999;159:2582–2588.
24. Mosen DM, Schatz M, Magid DJ, et al. The relationship between obesity and asthma severity and control in adults. J Allergy Clin Immunol. 2008;122:507–511.e6.
25. Sutherland ER, Goleva E, Strand M, et al. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med. 2008;178:682–687.
26. van Huistede A, Rudolphus A, Castro Cabezas M, et al. Effect of bariatric surgery on asthma control, lung function and bronchial and systemic inflammation in morbidly obese subjects with asthma. Thorax. 2015;70:659–667.
27. Tsai CL, Lee WY, Hanania NA, et al. Age-related differences in clinical outcomes for acute asthma in the United States, 2006–2008. J Allergy Clin Immunol. 2012;129:1252–1258.
28. Karlstad O, Nafstad P, Tverdal A, et al. Comorbidity in an asthma population 8-29 years old: a study from the Norwegian Prescription Database. Pharmacoeconomics Drug Saf. 2012;21:1045–1052.
29. Grupp-Phelan J, Lozano P, Fishman P. Health care utilization and cost in children with asthma and selected comorbidities. J Asthma. 2001;38:363–373.
30. Wardzynska A, Kubisk B, Kowalski ML. Comorbidities in elderly patients with asthma: association with control of the disease and concomitant treatment. Geriatr Gerontol Int. 2015;15:902–909.
31. Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128:2099–2107.
32. Zein JG, Dweik RA, Comhair SA, et al. Asthma is more severe in older adults. PLoS One. 2015;10:e0133490doi: 10.1371/journal.pone.0133490.
33. Yanez A, Cho SH, Soriano JB, et al. Asthma in elderly: what we know and what we have yet to know. World Allergy Organ J. 2014;7:8doi: 10.1186/1939-4551-7-8.
34. Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med. 2012;12:26.
35. Wijnhoven HA, Kriegsman DM, Hesselink AE, et al. The influence of co-morbidity on health-related quality of life in asthma and COPD patients. Respir Med. 2003;97:468–475.